Efficacy and safety of tolvaptan for hyponatremia：an overview of systematic reviews/meta-analysis
- VernacularTitle:托伐普坦治疗低钠血症有效性与安全性的系统评价/Meta分析再评价
- Author:
Xiaoxiao LIANG
1
,
2
;
Shuxian LYU
3
;
Shixian CHEN
1
;
Xiao LI
2
;
Ling LI
2
;
Xin HUANG
1
Author Information
1. School of Pharmacy，Shandong University of Traditional Chinese Medicine，Jinan 250355，China
2. Dept. of Pharmacy，the First Affiliated Hospital of Shandong First Medical University（Shandong Provincial Qianfoshan Hospital），Jinan 250014，China
3. School of Pharmacy，Shandong First Medical University，Jinan 250000，China
- Publication Type:Journal Article
- Keywords:
tolvaptan;
hyponatremia;
efficacy;
safety;
systematic reviews;
meta-analysis;
reevaluate
- From:
China Pharmacy
2023;34(8):983-987
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To reevaluate systematic reviews/meta-analysis of efficacy and safety of tolvaptan for hyponatremia. METHODS Retrieved from CNKI， Wanfang Data， VIP， CBM， PubMed， Embase and the Cochrane Library database， systematic reviews/meta-analysis about tolvaptan for the treatment of hyponatremia were included from the inception to June 15， 2022. After screening literature and extracting data， the PRISMA statement， AMSTAR 2 scale and GRADE method were used to evaluate the reporting quality， methodological quality and evidence quality of the included literature， respectively. RESULTS A total of 6 articles were included， of which 1 was systematic review and 5 were meta-analysis， including 56 outcome indicators. All of the 6 studies had PRISMA scores ranging from 15.0 to 20.5， and the quality of them was moderate. Results of the AMSTAR 2 scale showed that the methodological quality of 5 literatures were very low， and the quality of 1 literature was low. The quality of GRADE evidence showed that there were 6 moderate-quality indicators， 13 low-quality indicators， 35 very low-quality indicators， and 2 indicators that could not be assessed due to missing data. The main factors causing degradation were limitations， inconsistency， imprecision and publication bias. In terms of efficacy， tolvaptan could effectively increase the level of serum sodium， increase urine volume， reduce body weight， reduce abdominal circumference， relieve edema， and reduce alaninetransaminase level. In terms of safety， the incidence of total adverse drug reaction induced by tolvaptan was controversial； it may increase the risk of dry mouth， thirst， frequent urination or excessive correction of serum sodium. CONCLUSIONS Tolvaptan has great efficacy in the treatment of hyponatremia， but serum sodium overcorrection should be avoided in terms of safety. Relevant systematic reviews/meta-analysis have shortcomings of low reporting quality， methodological quality and evidence quality， which may reduce the reliability of the results， so the results should be treated with caution.
